controlled trial · 2021 · landmark
“In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo.”
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med
Who: Adults aged 18-85 with type 2 diabetes recently hospitalized for worsening heart failure treated with intravenous diuretics, clinically stable, with elevated natriuretic peptides, reduced or preserved ejection fraction
PMID 33200892
controlled trial · 2022 · landmark
“Initiation of the SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure resulted in a statistically significant and clinically meaningful benefit in the 90 days after randomization.”
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med
Who: Adults hospitalized for acute de novo or decompensated chronic heart failure, stabilized and randomized 1-5 days after admission, any ejection fraction, with or without diabetes; median age 71
PMID 35228754
pooled analysis · 2022 · landmark
“This meta-analysis of 21,947 patients with HF across the full spectrum of ejection fraction, including both outpatients and hospitalized patients, confirms that SGLT2i significantly reduce the risk of mortality and worsening HF and improve patient symptoms and overall health status when added to standard therapy for HF.”
SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet
Who: Patients with heart failure across the full ejection-fraction range, outpatients and those hospitalized for worsening heart failure, from DELIVER, EMPEROR-Preserved, DAPA-HF, EMPEROR-Reduced and SOLOIST-WHF
PMID 36041474
controlled trial · 2021 · landmark
“In conclusion, in patients with heart failure and a reduced ejection fraction, empagliflozin reduced the risk of inpatient and outpatient worsening heart failure events, benefits that were seen within 12 to 28 days of initiation of treatment and were sustained for the duration of double-blind therapy.”
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation
Who: EMPEROR-Reduced participants: adults with chronic NYHA class II-IV heart failure and ejection fraction 40% or less (enriched for 30% or less), on appropriate heart-failure therapy, with or without diabetes
PMID 33081531
controlled trial · 2020 · landmark
“In the DAPA-HF trial, treatment with dapagliflozin reduced death and HF hospitalizations across the range of baseline KCCQ values, and improved symptom burden, functional status, and quality of life in patients with HFrEF.”
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. Circulation
Who: DAPA-HF participants: adults with NYHA class II or higher heart failure, ejection fraction 40% or less, elevated NT-proBNP, optimally treated; 4443 with baseline KCCQ data
PMID 31736335